Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

HeartBeam, Inc. BEAT NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Healthcare Information Services • US • USD

SharesGrow Score
49/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$5.00
+316.7%

HeartBeam, Inc. (BEAT) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $1.20. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is BEAT = $5 (+316.7% upside).

Valuation: BEAT trades at a trailing Price-to-Earnings (P/E) of -1.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.

Net income is $21M (loss), growing at -17.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $3M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 1.45 (adequate). Debt-to-assets is 0%. Total assets: $6M.

Analyst outlook: 9 / 13 analysts rate BEAT as buy (69%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 75/100 (Pass), Moat 28/100 (Fail), Future 73/100 (Pass), Income ?/100 (Fail).

$5.00
▲ 316.67% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for HeartBeam, Inc., the average price target is $5.00, with a high forecast of $5.50, and a low forecast of $4.00.
Highest Price Target
$5.50
Average Price Target
$5.00
Lowest Price Target
$4.00

BEAT SharesGrow Score Overview

58/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BEAT

✓
VALUE Pass
100/100
BEAT trades at a trailing Price-to-Earnings (P/E) of -1.9 (S&P 500 average ~25). Forward PEG 0.11 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $5, implying +316.7% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
BEAT: +0%/yr revenue is, -17.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet BEAT: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 1.45 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
BEAT: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 9 / 13 analysts rate BEAT as buy (69%). Analyst consensus target is $5 (+316.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.54-4
Volume488.39K
Avg Volume (30D)1.19M
Market Cap$41.33M
Beta (1Y)-0.64
Share Statistics
EPS (TTM)-0.62
Shares Outstanding$33.71M
IPO Date2021-11-11
Employees21
CEORobert Eno
Financial Highlights & Ratios
Gross Profit$-40K
EBITDA$-21.14M
Net Income$-21.02M
Operating Income$-21.14M
Total Cash$4.38M
Net Debt$-4.38M
Total Assets$5.84M
Price / Earnings (P/E)-1.9
Analyst Forecast
1Y Price Target$5.50
Target High$5.50
Target Low$4.00
Upside+358.3%
Rating ConsensusBuy
Analysts Covering13
Buy 69% Hold 31% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS42238H1086

Price Chart

Track all markets on TradingView
BEAT
HeartBeam, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Healthcare Information Services
0.54 52WK RANGE 4.00

People Also View

NUTX
NUTX
Nutex Health, Inc.
$107.84
+1.48%
 LIFW
LIFW
MSP Recovery, Inc.
$3.24
+0.00%
 EUDA
EUDA
EUDA Health Holdings Limited
$6.88
+1.03%
 BFRG
BFRG
Bullfrog AI Holdings, Inc. Common Stock
$1.01
-3.81%
 HLTH
HLTH
Cue Health Inc.
$0.04
-29.77%
 MGRX
MGRX
Mangoceuticals, Inc.
$0.39
-1.35%
 HCTI
HCTI
Healthcare Triangle, Inc.
$2.60
+3.17%
 FOXO
FOXO
FOXO Technologies Inc.
$0.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message